CN106946968B - 一种异黄芪甲苷的合成方法 - Google Patents
一种异黄芪甲苷的合成方法 Download PDFInfo
- Publication number
- CN106946968B CN106946968B CN201710188497.8A CN201710188497A CN106946968B CN 106946968 B CN106946968 B CN 106946968B CN 201710188497 A CN201710188497 A CN 201710188497A CN 106946968 B CN106946968 B CN 106946968B
- Authority
- CN
- China
- Prior art keywords
- compound
- solvent
- room temperature
- synthesizing
- steps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930186049 Isoastragaloside Natural products 0.000 title claims abstract description 20
- 238000010189 synthetic method Methods 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- WENNXORDXYGDTP-UOUCMYEWSA-N cycloastragenol Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O)C4(C)C)[C@H]4[C@@H](O)C[C@H]3[C@]2(C)C[C@@H]1O WENNXORDXYGDTP-UOUCMYEWSA-N 0.000 claims abstract description 24
- WENNXORDXYGDTP-UHFFFAOYSA-N cyclosiversigenin Natural products O1C(C(C)(O)C)CCC1(C)C1C2(C)CCC34CC4(CCC(O)C4(C)C)C4C(O)CC3C2(C)CC1O WENNXORDXYGDTP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 16
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical class O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims abstract description 15
- 125000006239 protecting group Chemical group 0.000 claims abstract description 15
- 229940126214 compound 3 Drugs 0.000 claims abstract description 14
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 36
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 36
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 34
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 26
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 24
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 20
- 238000004809 thin layer chromatography Methods 0.000 claims description 19
- 229940125782 compound 2 Drugs 0.000 claims description 17
- 239000003054 catalyst Substances 0.000 claims description 14
- 229940125898 compound 5 Drugs 0.000 claims description 14
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 13
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 13
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 12
- 239000000348 glycosyl donor Substances 0.000 claims description 12
- 238000006206 glycosylation reaction Methods 0.000 claims description 12
- 239000002808 molecular sieve Substances 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- MSSYPWFHLFBMMP-BQAOMNQWSA-N Isoastragaloside IV Chemical compound C[C@]12CC[C@@]34C[C@@]35CC[C@@H](C([C@@H]5[C@H](C[C@H]4[C@@]1(C[C@@H]([C@@H]2[C@]6(CC[C@H](O6)C(C)(C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)O)C)O)(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O MSSYPWFHLFBMMP-BQAOMNQWSA-N 0.000 claims description 10
- 229960000583 acetic acid Drugs 0.000 claims description 10
- 239000012362 glacial acetic acid Substances 0.000 claims description 10
- 239000002274 desiccant Substances 0.000 claims description 8
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical group [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 8
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 claims description 7
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 claims description 7
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 claims description 7
- -1 lithium aluminum hydride Chemical compound 0.000 claims description 7
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical group CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims description 7
- 150000004756 silanes Chemical class 0.000 claims description 6
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 5
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000011261 inert gas Substances 0.000 claims description 5
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 2
- 229910000085 borane Inorganic materials 0.000 claims description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 claims 2
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- 241001061264 Astragalus Species 0.000 description 7
- 235000006533 astragalus Nutrition 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 210000004233 talus Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 239000000386 donor Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 150000007949 saponins Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DOXNDFPXMBXOKH-UHFFFAOYSA-N [Au+2] Chemical compound [Au+2] DOXNDFPXMBXOKH-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005858 glycosidation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
本发明公开了一种异黄芪甲苷的合成方法,包括以下步骤:将环黄芪醇的3位羟基以保护基R1保护,6位和16位羟基以保护基R2保护后得到化合物3,将化合物3进行糖苷化反应,后脱除3位保护基R1,继续进行发生糖苷化反应,得到化合物8,所有保护基脱除,得到异黄芪甲苷1,本发明是高效、高立体选择性的异黄芪甲苷合成方法,为异黄芪甲苷的研究及应用提供足够的原料,为异黄芪苷类化合物的合成提供参考,填补现有技术的空白,将大大推进黄芪皂苷类化合物的活性机理研究及其药物开发的进程。
Description
技术领域
本发明属于化学合成领域,更具体的涉及一种异黄芪甲苷的制备方法。
背景技术
黄芪为补药之首,属于豆科黄芪属植物。近年来随着现代分离和鉴定技术的发展,从黄芪中分离出了大量三萜皂苷、黄酮类化合物以及多糖类成分。后期的生物生化实验表明黄芪的药用功效主要通过黄芪皂苷表现出来。近期研究表明,黄芪皂苷在免疫调节,降糖,改善胰岛素抵抗活性,抗肿瘤,对心血管***调节以及抗病毒,抗氧化活性等方面都表现出了极为可喜的药用前景,并且在众多黄芪皂苷中,以黄芪甲苷和异黄芪甲苷的活性最好。
尽管黄芪皂苷广泛的应用前景促使人们对其研究不断深入,但目前用于活性测试的黄芪皂苷多为从黄芪中分离提取所得,由于黄芪中所含皂苷种类繁多,且结构类似,这给分离提纯带来很大困难。还有一些黄芪皂苷为次生皂苷,在黄芪中的含量很低,要得到足够量以供活性测试之用更是不易,这已成为制约黄芪皂苷活性研究深入的瓶颈,到目前为止几乎没有关于黄芪皂苷的化学合成研究报道。
异黄芪甲苷在黄芪中的含量特别少,其分子结构式如下:
其皂苷部分为环黄芪醇,由于环黄芪醇(化合物1)的3位,6位,16位及25位含有4个惰性OH,特别是25位羟基为叔羟基活性低,糖苷化反应困难,并且4个惰性OH相互之前的反应活性难以区分,选择性的糖苷化其中部分羟基更为困难。
环黄芪醇的羟基保护反应进行困难且产物复杂多变,有文献报道,在过量乙酰化试剂作用下,60℃,长达50天的反应时间下,仅能得到56%收率的全乙酰化的环黄芪醇。缩短反应时间或降低反应温度导致反应产物十分复杂,为4个羟基中随机的1或2个羟基被保护的环黄芪醇。由此可见异黄芪甲苷合成困难,国内外至今未见成功的报道。
参考文献:a)Mamedova,R.P.;Agzamova,M.A.;Isaev,M.I.Chem.Nat.Compd.2001,37,533-536.b)Isaev,I.M.;Iskenderov,D.A.;Isaev,M.I.Chem.Nat.Compd.2009,45,381-384.c)Isaev,I.M.;Iskenderov,D.A.;Isaev,M.I.Chem.Nat.Compd.2010,46,407-411.d)Procopiou,P.A.;Baugh,S.P.D.;Flack,S.S.;Inglis,G.G.J.Org.Chem.1998,63,2342-2347.
发明内容
本发明提供一种异黄芪甲苷的合成方法,能高效、高选择性的合成异黄芪甲苷,为异黄芪甲苷的研究及应用提供足够的原料,为异黄芪苷类化合物的合成提供参考。
本发明通过以下步骤来实现的:
一种异黄芪甲苷的合成方法,包括以下步骤:
(1)将环黄芪醇的3位羟基以保护基R1保护,得到化合物2;
(2)将化合物2的6位和16位羟基以保护基R2保护,得到化合物3;
(3)将化合物3与糖基给体化合物4发生糖苷化反应,得到化合物5;
(4)将化合物5的3位保护基R1脱除,得到化合物6;
(5)将化合物6与糖基给体化合物7发生糖苷化反应,得到化合物8;
(6)将化合物8的所有保护基脱除,得到异黄芪甲苷;
其中,所述R1选自取代或非取代的C1-C9烷硅基;所述R2选自取代或非取代的C2-C6烷酰基;所述R3或R4各自独立的选自C1-C6芳酰基;X选自取代或非取代的炔苯甲酰氧基。
上述步骤(1)中,所述保护的方法包括以下步骤:室温下,将环黄芪醇溶于第一溶剂中,再加入卤代硅烷和咪唑,将反应温度缓慢升至室温后搅拌直到TLC跟踪显示环黄芪醇反应完全;所述第一溶剂为二氯甲烷、二氯乙烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、冰醋酸、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种,所述环黄芪醇、卤代硅烷和咪唑的摩尔比为1:1:1~1:5:10,优选为1:2:3~1:4:6,所述环黄芪醇在第一溶剂中的浓度为0.1~1mol/L,优选为0.45~0.5mol/L,所述卤代硅烷为TBSCl、TESCl、TBDMSCl、TBDPSCl、DIPSCl、DPSCl或TIPDSCl。
上述步骤(2)中,所述保护的方法包括以下步骤:0℃以下,将化合物2溶于第二溶剂中,再加入特戊酰氯,将反应温度缓慢升至室温后再加热到50℃,继续搅拌直到TLC跟踪显示化合物2反应完全,所述第二溶剂为二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种;所述化合物2和特戊酰氯的摩尔比为1:2~1:20,优选为1:2~1:10;所述化合物2在第二溶剂中的浓度为0.1~1mol/L,优选为0.108~0.5mol/L。
上述步骤(3)中,所述糖苷化反应包括以下步骤:在惰性气体保护下,将化合物3和糖基给体化合物4溶于第三溶剂中,并加入干燥剂,在室温下搅拌0.5~2小时再加入催化剂,继续在室温下搅拌直到TLC跟踪显示化合物2反应完全;所述第三溶剂为二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、冰醋酸、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种,所述催化剂为一价金的络合物,优选为PPh3AuNTf2或PPh3AuOTf;所述化合物3、糖基给体化合物4和所述催化剂的摩尔比为1:1:0.1~1:5:0.8,优选为1:1:0.1~1:2:0.5;所述化合物3在第三溶剂中的浓度为0.001~1mol/L,优选为0.006~0.05mol/L;所述干燥剂为分子筛,优选为分子筛或酸洗的分子筛,更优选为4A分子筛。
上述步骤(4)中,所述保护基R1脱除的方法包括以下步骤:室温下,将化合物5溶于第四溶剂中,再加入樟脑磺酸,搅拌直到TLC跟踪显示化合物5反应完全;所述第四溶剂为二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、冰醋酸、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种,所述化合物5和樟脑磺酸的摩尔比1:1~1:10,优选为1:1~1:4;所述化合物5在第四溶剂中的浓度为0.001~1mol/L,优选为0.001~0.004mol/L。
上述步骤(5)中,所述糖苷化反应包括以下步骤:将化合物6和糖基给体化合物7溶于第五溶剂中,并加入干燥剂,在室温下搅拌0.5~2小时再加入催化剂,继续在室温下搅拌直到TLC跟踪显示化合物6反应完全,所述第五溶剂为二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、冰醋酸、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种;所述化合物6、糖基给体化合物7和所述催化剂的摩尔比为1:1:0.1~1:5:0.8,优选为1:1:0.1~1:2.5:1;所述化合物6在第五溶剂中的浓度为0.001~1mol/L,优选为0.001~0.003mol/L;所述催化剂为一价金的络合物,优选为PPh3AuNTf2或PPh3AuOTf;所述干燥剂为分子筛,优选为分子筛或酸洗的分子筛,更优选为4A分子筛。
上述步骤(6)中,所述保护基脱除的反应包括以下步骤:将化合物8溶于第六溶剂中,再加入还原剂,室温下搅拌直到TLC跟踪显示化合物8反应完全;所述还原剂为硼氢化钠,氢化铝锂,硼烷;所述第八溶剂为二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、冰醋酸、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种,优选为甲醇。
优选的,上述步骤(1)~(6)中的任一步骤均在惰性气体保护条件下进行,所述惰性气体选自氮气、氩气或氦气。
步骤(1)中,当环黄芪醇,TBSCl和咪唑的摩尔比为1:20:20时,得到的是环黄芪醇3位和6位羟基全部保护的化合物,当环黄芪醇,TBSCl和咪唑的摩尔比为1:2:2时,其他反应参数相同,反应收率只有40%。
本发明的技术效果是:本发明是高效、高立体选择性的异黄芪甲苷合成方法,为异黄芪甲苷的研究及应用提供足够的原料,为异黄芪苷类化合物的合成提供参考,填补现有技术的空白,将大大推进黄芪皂苷类化合物的活性机理研究及其药物开发的进程。
具体实施方式
根据下述实施例,可以更好地理解本发明,然而,本领域的技术人员容易理解,实施例所描述的内容仅用于说明本发明,而不应当也不会限制权利要求书中所详细描述的本发明。
Bz保护的糖4和7按照本领域常规方法合成:
化合物4-1的合成方法如下:
在氮气保护,将异头位羟基裸露的全Bz葡萄糖(100mg,0.17mmol)溶于干燥的二氯甲烷(4mL)中,再向体系中加入邻炔基苯甲酸(37.4mg,0.2mmol),DMAP(28.1mg,0.23mmol),EDCI(43.9mg,0.23mmol),DIPEA(74μL),室温下搅拌过夜直到TLC跟踪显示原料反应完全,将反应体系用二氯甲烷萃取,并依次用1mol/l HCl、饱和碳酸氢钠、饱和NaCl洗,无水硫酸钠干燥,抽滤,减压浓缩粗产品,然后柱层析得到白色固体化合物4-1(121mg,93%):1H NMR(400MHz,CDCl3)δ1H NMR(400MHz,CDCl3)δ8.07(d,J=7.5Hz,2H),7.92-7.87(m,6H),7.44-7.28(m,17H),6.94(d,J=3.3Hz,1H),6.38(dd,J=9.6,9.9Hz,1H),5.94(dd,J=9.9,10.2Hz,1H),5.76(dd,J=3.3,9.9Hz,1H),4.80-4.66(m,2H),4.54(dd,J=3.3,6.0Hz,1H),1.56(m,1H),0.84(d,J=6.6Hz,4H).
化合物7-1的合成方法如下:
类似于合成化合物4-1,从异头位羟基裸露的全Bz木糖得到白色固体化合物7-1(612mg,89%):[α]D 25=0.02(c 1.0,CHCl3);1H NMR(400MHz,CDCl3)δ8.04-7.98(m,6H),7.90(dd,J=1.2,8.0Hz,1H),7.58-7.51(m,3H),7.49-7.42(m,2H),7.38-7.30(m,6H),7.21(td,J=1.6,7.6Hz,1H),6.42(d,J=7.6Hz,1H),5.81(t,J=5.2Hz,1H),5.58(dd,J=4.0,5.2Hz,1H),5.36-5.32(m,1H),4.63(dd,J=3.6,12.8Hz,1H),4.06(dd,J=4.8,12.4Hz,1H),1.54-1.47(m,1H),0.90-0.84(m,4H);13C NMR(100MHz,CDCl3)δ164.9,164.4,164.3,163.3,133.7,132.8,129.9,129.7,129.4,129.3,128.5,128.3,127.8(2C),126.3,124.7,99.7,91.4,73.6,67.8,67.6,67.2,60.9,8.2,-0.0;HRMS(ESI-TOF)m/z:[M+H]+calcd forC38H31O9 631.1968;found 631.1966.
实施例1
异黄芪甲苷的合成,
(1)3位羟基保护的环黄芪醇衍生物2的合成,
在氮气保护下,环黄芪醇(400mg,0.82mmol)溶于干燥的DMF再向体系中加入TBSCl(489mg,3.3mmol),咪唑(333mg,4.9mmol),在室温搅拌直到TLC跟踪显示原料反应完全,将反应体系用乙酸乙酯萃取,并依次用1mol/l HCl、饱和碳酸氢钠、饱和NaCl洗,无水硫酸钠干燥,抽滤,减压浓缩粗产品,然后柱层析得到白色固体化合物2(76.8%):[α]D 25=30.5(c=1,CHCl3);1H NMR(400MHz,CDCl3)δ4.67(dd,J=7.6,14.4Hz,1H),3.72(dd,J=6.0,8.0Hz,1H),3.51(td,J=3.6,9.6Hz,1H),3.25(dd,J=4.8,10.0Hz,1H),2.59(dd,J=10.4,21.6Hz,1H),2.31(d,J=8.0Hz,1H),2.00-1.92(m,4H),1.76(dd,J=4.0,12.0Hz,1H),1.25(s,3H),1.21(s,3H),1.17(s,3H),1.13(s,3H),1.11(s,3H),1.09(s,3H),0.91(s,3H),0.89(s,3H),0.85(s,9H),0.47(d,J=4.0Hz,1H),0.31(d,J=4.4Hz,1H),0.00(s,3H),-0.005(s,3H);13C NMR(100MHz,CDCl3)δ87.1,81.4,78.8,73.4,71.8,68.9,57.5,53.7,46.9,46.5,46.0,45.0,42.1,37.7,34.4,33.0,32.1,31.4,30.8,29.4,28.6,27.9,27.7,26.4,25.9(2C),25.8,21.4,20.5,20.0,18.1,15.8;HRMS(ESI)calcd for C36H65O5Si[M+H]+605.4596,found 605.4599;
(2)3,6和16位羟基保护的环黄芪醇衍生物3的合成,
在氮气保护,0摄氏度条件下,将化合物2(300mg,0.5mmol)溶于干燥的吡啶(2ml)中,再向体系中加入PivCl(50μL,4.96mmol),缓慢升至室温后加热到50度,搅拌直到TLC跟踪显示原料反应完全,将反应体系用乙酸乙酯萃取,并依次用1mol/l HCl、饱和碳酸氢钠、饱和NaCl洗,无水硫酸钠干燥,抽滤,减压浓缩粗产品,然后柱层析得到白色固体化合物3(94.9%):[α]D 25=72.9(c=1,CHCl3);1H NMR(400MHz,CDCl3)δ5.31-5.26(m,1H),4.74-4.69(m,1H),3.74(t,J=7.2Hz,1H),3.24(dd,J=4.8,10.0Hz,1H),2.37(d,J=8.0Hz,1H),2.08-2.00(m,2H),1.36(s,3H),1.31(s,3H),1.18(s,3H),1.16(s,9H),1.13(s,9H),1.07(s,3H),0.96(s,3H),0.85(s,12H),0.80(s,3H),0.54(d,J=4.8Hz,1H),0.21(d,J=4.8Hz,1H);13C NMR(100MHz,CDCl3)δ178.2,177.7,85.5,83.3,78.5,75.7,71.2,69.7,57.5,49.2,46.7,46.2,45.1,43.0,41.9,38.6,38.2,32.5,31.9,31.4,27.8,27.4,27.3,27.2,27.1(2C),26.6,26.2,26.0,25.9,25.4,24.5,20.7,19.8,19.6,18.1,15.4;HRMS(ESI)calcdfor C64H81O7Si[M+H]+773.5746,found 773.5743;
(3)25位糖苷化产物5的合成,
在氮气保护下,将化合物3和葡萄糖炔酯给体4-1溶于干燥的二氯甲烷中,并加入4A分子筛,在室温下搅拌半个小时再加入催化剂Ph3PAuNTf2(0.2eq),继续在室温下搅拌直到TLC跟踪显示原料反应完全,减压浓缩粗产品,然后柱层析得到白色固体化合物5(91.6%):[α]D 25=40.3(c=1,CHCl3);1H NMR(400MHz,CDCl3)δ8.02-7.96(m,4H),7.91(dd,J=1.2,8.0Hz,2H),7.86(dd,J=1.2,8.4Hz,2H),7.54-7.48(m,4H),7.43-7.34(m,7H),7.31(t,J=8.0Hz,1H),5.90(t,J=9.6Hz,1H),5.53(dd,J=9.2,10.0Hz,1H),5.48(dd,J=7.6,9.2Hz,1H),5.35(d,J=8.0Hz,1H),5.23-5.18(m,1H),4.76(dd,J=6.8,14.4Hz,1H),4.60(dd,J=2.8,12.0Hz,1H),4.44(dd,J=7.2,12.0Hz,1H),4.13-4.08(m,1H),3.72(dd,J=4.8,8.4Hz,1H),3.20(m,1H),2.42(d,J=7.6Hz,1H),2.14-2.06(m,2H),1.37(s,3H),1.33(s,3H),1.18(s,9H),1.17(s,9H),1.16(s,3H),1.13(s,3H),0.98(s,3H),0.86(s,12H),0.80(s,3H),0.56(d,J=4.8Hz,1H),0.27(d,J=4.8Hz,1H);13C NMR(100MHz,CDCl3)δ178.0,177.7,165.9,165.8,165.4,164.9,134.2,134.1,133.5,133.2,133.1(2C),129.8(2C),129.7(2C),129.6,129.3,129.2,129.0,128.8,128.4,128.3(2C),96.2,86.0,84.1,80.1,78.3,76.1,73.1,72.1(2C),70.5,69.8,63.9,57.8,49.1,46.8,46.3,45.2,43.2,41.9,38.6,38.5,38.2,32.6,32.1,31.2,30.5,27.8,27.4,27.2(2C),25.9,25.5,24.0,21.7,20.6,19.7,19.6,18.1,15.4,-3.9,-4.9;HRMS(ESI)calcd for C80H107O16Si[M+H]+1351.73229,found 1351.73310;
(4)3位羟基裸露产物6的合成,
在氮气保护下,将化合物5(20mg,0.03mmol)溶于干燥的甲醇(2.0mL)中,在室温下加入樟脑磺酸(26mg,0.11mmol),搅拌直到TLC跟踪显示原料反应完全,减压浓缩粗产品,然后柱层析得到白色固体化合物6(82.9%):[α]D 25=20.5(c=1,CHCl3);1H NMR(400MHz,CDCl3)δ8.00-7.96(m,4H),7.91(dd,J=1.2,8.0Hz,2H),7.85(dd,J=1.2,8.0Hz,2H),7.54-7.49(m,3H),7.45-7.33(m,7H),7.31-7.27(m,2H),5.91(t,J=9.6Hz,1H),5.54(t,J=10.1Hz,1H),5.48(dd,J=8.0,9.6Hz,1H),5.27(d,J=8.0Hz,1H),5.23-5.18(m,1H),4.78-4.73(m,1H),4.59(dd,J=3.2,12.0Hz,1H),4.44(dd,J=7.2,11.6Hz,1H),4.14-4.08(m,1H),3.72(dd,J=4.8,8.4Hz,1H),3.24(dd,J=4.8,11.6Hz,1H),2.43(d,J=8.0Hz,1H),2.16(dd,J=7.6,13.6Hz,1H),2.05-2.01(m,1H),1.36(s,3H),1.33(s,3H),1.18(s,12H),1.17(s,9H),1.11(s,3H),1.00(s,3H),0.91(s,3H),0.89(s,3H),0.56(d,J=4.8Hz,1H),0.30(d,J=4.4Hz,1H);13C NMR(100MHz,CDCl3)δ178.1,177.7,166.0,165.8,165.4,164.9,133.5,133.2(2C),133.1,129.8(2C),129.7(2C),129.6(2C),128.9,128.8,128.4,128.3(2C),96.2,86.0,84.1,80.1,77.9,76.1,73.1,72.1,72.0,70.4,69.9,63.9,57.8,49.2,46.8,46.3,45.4,43.7,41.3,38.6,38.5,38.3,32.3(2C),31.3,30.0,28.0,27.3,27.2,27.1,26.9,26.1,25.9,25.6,23.8,22.0,20.8,19.8,19.7,15.0;HRMS(ESI)calcdfor C74H93O16[M+H]+1237.64581,found 1237.64675;
(5)3,25位糖苷化产物8的合成,
在氮气保护下,将化合物6和木糖炔酯给体7溶于干燥的二氯甲烷中,并加入4A分子筛,在室温下搅拌半个小时再加入催化剂Ph3PAuNTf2(0.2eq),继续在室温下搅拌直到TLC跟踪显示原料反应完全,减压浓缩粗产品,然后柱层析得到白色固体化合物8(83.2%):[α]D 25=25.2(c=0.3,CHCl3);1H NMR(400MHz,CDCl3)δ8.02-7.94(m,10H),7.92(dd,J=1.2,8.0Hz,2H),7.86(dd,J=1.2,8.0Hz,2H),7.55-7.43(m,7H),7.41-7.27(m,14H),5.91(t,J=10.0Hz,1H),5.80(t,J=8.0Hz,1H),5.52-5.42(m,3H),5.32-5.27(m,2H),5.23-5.18(m,1H),4.80(d,J=6.4Hz,1H),4.65-4.58(m,2H),4.42-4.33(m,2H),4.14-4.09(m,1H),3.73(dd,J=4.8,8.4Hz,1H),3.62(dd,J=7.6,12.0Hz,1H),3.15(dd,J=4.4,11.2Hz,1H),2.44(d,J=7.6Hz,1H),2.13-2.03(m,2H),1.35(s,3H),1.33(s,3H),1.19(s,3H),1.17(s,9H),1.13(s,3H),1.08(s,9H),0.97(s,3H),0.78(s,3H),0.64(s,3H),0.52(d,J=4.8Hz,1H),0.26(d,J=4.8Hz,1H);13C NMR(100MHz,CDCl3)δ178.0,177.5,166.0,165.9,165.6(2C),165.4,165.1,164.9,133.6,133.4,133.3,133.2(2C),133.1,129.9,129.8,129.7(2C),129.6(2C),129.4,129.2,129.1,128.9,128.8,128.5,128.4(2C),128.3(2C),102.6,96.2,88.6,86.1,84.2,80.2,76.1,73.1,72.1(2C),71.2,71.0,70.4,69.6,69.3,63.9,61.7,57.8,49.2,46.8,46.3,45.2,42.9,41.4,38.5,38.3,32.5,31.8,31.1,28.6,27.4,27.2,27.1,26.6,26.2,25.9,25.6,24.0,21.9,20.7,19.7,19.6,15.6;HRMS(ESI)calcd for C100H116O23N[M+NH4]+1699.79666,found 1699.79904;
(6)异黄芪甲苷的合成,
在氮气保护0摄氏度的条件下,将化合物13(70mg,0.042mmol)溶于干燥的THF中,往体系中缓慢加入锂铝氢(25mg,0.67mmol),再缓慢升至室温搅拌直到TLC跟踪显示原料反应完全,减压浓缩粗产品,然后柱层析得到白色固体化合物异黄芪甲苷(收率:75.6%)::[α]D 25=7.9(c=0.25,CH3OH);1H NMR(400MHz,C5D5N)δ5.08(d,J=7.6Hz,1H),4.93(d,J=7.2Hz,1H),4.45(dd,J=3.6,11.6Hz,1H),4.40(dd,J=4.8,11.2Hz,1H),4.32(dd,J=4.8,11.6Hz,1H),4.25-4.15(m,4H),4.09-4.00(m,3H),3.92-3.88(m,2H),3.81-3.72(m,2H),3.64-3.61(m,1H),2.85(dd,J=11.6,19.6Hz,1H),2.48(d,J=7.6Hz,1H),2.00(s,3H),1.67(s,3H),1.42(s,3H),1.35(s,3H),1.33(s,3H),1.29(s,3H),0.94(s,3H),0.56(d,J=3.2Hz,1H),0.28(d,J=4.0Hz,1H);13C NMR(100MHz,C5D5N)δ107.4,98.6,88.4,87.0,81.8,78.3,77.8,75.4,75.0,73.3,71.1,71.0,67.7,66.8,62.5,57.9,53.8,46.6,45.9,45.8,45.0,42.5,38.4,34.8,33.2,32.2,30.3,30.1,29.3,28.7,27.6,26.0,25.7,25.4,22.8,21.3,20.7,19.8,16.4;HRMS(ESI)calcd for C41H68O14Na[M+Na]+807.4501,found807.4498。
对比例1:步骤(3)或(5)中,用三氯乙酰亚胺酯给体代替炔酯给体进行糖苷化反应时反应体系很杂,产物少,说明炔酯给体在合成异黄芪甲苷时更具优越性。
对比例2:步骤(1)中,所述环黄芪醇、卤代硅烷和咪唑的摩尔比为1:20:20时,其他反应参数相同,反应为3,6位羟基同时保护的产物。
对比例3:步骤(1)中,当环黄芪醇,TBSCl和咪唑的摩尔比为1:2:2时,其他反应参数相同,反应收率只有40%。
对比例4:步骤(2)中,化合物2的浓度为0.001mol/L时,其他反应参数相同,化合物2只有6羟基得到保护。
Claims (8)
2.根据权利要求1所述的一种异黄芪甲苷的合成方法,其特征在于,步骤(1)中,所述保护的方法包括以下步骤:室温下,将环黄芪醇溶于第一溶剂中,再加入卤代硅烷和咪唑,将反应温度缓慢升至室温后搅拌直到TLC跟踪显示环黄芪醇反应完全;所述第一溶剂为二氯甲烷、二氯乙烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、冰醋酸、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种,所述卤代硅烷为TBSCl、TESCl、TBDMSCl、TBDPSCl、DIPSCl、DPSCl或TIPDSCl,所述环黄芪醇、卤代硅烷和咪唑的摩尔比为1:1:3~1:5:10;所述环黄芪醇在第一溶剂中的浓度为0.1~1mol/L。
3.根据权利要求1所述的一种异黄芪甲苷的合成方法,其特征在于,步骤(2)中,所述保护的方法包括以下步骤:0℃以下,将化合物2溶于第二溶剂中,再加入特戊酰氯,将反应温度缓慢升至室温后再加热到50℃,继续搅拌直到TLC跟踪显示化合物2反应完全,所述第二溶剂为二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种;所述化合物2和特戊酰氯的摩尔比为1:2~1:20;所述化合物2在第二溶剂中的浓度为0.1~1mol/L。
4.根据权利要求1所述的一种异黄芪甲苷的合成方法,其特征在于,步骤(3)中,所述糖苷化反应包括以下步骤:在惰性气体保护下,将化合物3和糖基给体化合物4溶于第三溶剂中,并加入干燥剂,在室温下搅拌0.5~2小时再加入催化剂,继续在室温下搅拌直到TLC跟踪显示化合物3反应完全;所述第三溶剂为二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、冰醋酸、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种,化合物3、糖基给体化合物4和所述催化剂的摩尔比为1:1:0.1~1:5:0.8;所述化合物3在第三溶剂中的浓度为0.001~1mol/L;所述催化剂选自一价金的络合物;所述干燥剂选自分子筛。
5.根据权利要求1所述的一种异黄芪甲苷的合成方法,其特征在于,步骤(4)中,所述保护基R1脱除的方法包括以下步骤:室温下,将化合物5溶于第四溶剂中,再加入樟脑磺酸,搅拌直到TLC跟踪显示化合物5反应完全;所述第四溶剂为二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、冰醋酸、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种,所述化合物5和樟脑磺酸的摩尔比1:1~1:10;所述化合物5在第四溶剂中的浓度为0.001~1mol/L。
6.根据权利要求1所述的一种异黄芪甲苷的合成方法,其特征在于,步骤(5)中,所述糖苷化反应包括以下步骤:将化合物6和糖基给体化合物7溶于第五溶剂中,并加入干燥剂,在室温下搅拌0.5~2小时再加入催化剂,继续在室温下搅拌直到TLC跟踪显示化合物6反应完全,所述第五溶剂为二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、冰醋酸、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种;所述化合物6、糖基给体化合物7和所述催化剂的摩尔比为1:1:0.1~1:5:0.8;所述化合物6在第五溶剂中的浓度为0.001~1mol/L;所述催化剂选自一价金的络合物;所述干燥剂选自分子筛。
7.根据权利要求1所述的一种异黄芪甲苷的合成方法,其特征在于,步骤(6)中,所述保护基脱除的反应包括以下步骤:将化合物8溶于第六溶剂中,再加入还原剂,室温下搅拌直到TLC跟踪显示化合物8反应完全;所述还原剂为硼氢化钠,氢化铝锂,硼烷;所述第六溶剂为二氯甲烷、氯仿、四氯化碳、1,2-二氯乙烷、DMF、甲苯、苯、二氧六环、吡啶、冰醋酸、四氢呋喃、三乙胺、乙酸乙酯、丙酮、甲醇、乙醇、DMSO或***中的一种或多种。
8.根据权利要求1所述的异黄芪甲苷的合成方法,其特征在于,步骤(1)~(6)中的任意步骤在惰性气体保护条件下进行。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710188497.8A CN106946968B (zh) | 2017-03-27 | 2017-03-27 | 一种异黄芪甲苷的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710188497.8A CN106946968B (zh) | 2017-03-27 | 2017-03-27 | 一种异黄芪甲苷的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106946968A CN106946968A (zh) | 2017-07-14 |
CN106946968B true CN106946968B (zh) | 2020-01-03 |
Family
ID=59473128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710188497.8A Expired - Fee Related CN106946968B (zh) | 2017-03-27 | 2017-03-27 | 一种异黄芪甲苷的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106946968B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100384830C (zh) * | 2006-01-12 | 2008-04-30 | 天津药物研究院 | 环黄芪醇类衍生物以及用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9248088B2 (en) * | 2003-06-25 | 2016-02-02 | Telomerase Activation Sciences, Inc. | Compositions and methods for skin conditioning |
-
2017
- 2017-03-27 CN CN201710188497.8A patent/CN106946968B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100384830C (zh) * | 2006-01-12 | 2008-04-30 | 天津药物研究院 | 环黄芪醇类衍生物以及用途 |
Also Published As
Publication number | Publication date |
---|---|
CN106946968A (zh) | 2017-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4856071B2 (ja) | 20(S)−ジンセノサイドRh2の合成方法 | |
CN110776544B (zh) | 一类2,3-不饱和半乳糖硫苷类化合物及其合成方法 | |
CN105263945B (zh) | 一种酸催化醛糖或酮糖直接与苷元反应制备皂苷的方法 | |
CN113527388A (zh) | 一种β-2-脱氧糖、2-脱氧-2-叠氮糖和葡萄糖苷键立体选择性合成的方法 | |
CN113603730B (zh) | 硼酸三酯为糖受体选择性合成氧糖苷或2-脱氧糖的方法 | |
CN104693266B (zh) | 一种改良的Fischer型糖苷化反应在构建皂苷中糖苷键的应用 | |
WO2018145578A1 (zh) | 一种黄芪甲苷的合成方法 | |
CN106946968B (zh) | 一种异黄芪甲苷的合成方法 | |
EP2625183B1 (en) | Process for the preparation of disaccharides applied to heparin pentasaccharides | |
CN107226830B (zh) | 一种乙基多杀菌素的化学合成方法 | |
CN109836465B (zh) | 一种制备盐酸表柔比星的方法 | |
EP1715880A2 (en) | AN EFFICIENT METHOD TO SYNTHESIZE BENZYL GROUP-PROTECTED ALPHA-PENTAGALLOYLGLUCOSE (&Agr;-PGG) AND ITS ANALOGUES | |
Iorizzi et al. | Starfish saponins, 48. isolation of fifteen sterol constituents (six glycosides and nine polyhydroxysteroids) from the starfish Solaster borealis | |
CN113185501B (zh) | 一种天然产物夏佛塔苷的高效全合成方法及应用 | |
WO2008105593A1 (en) | METHOD FOR STEREOSELECTIVE PREPARATION AND SEPARATION OF TRI-O-ACETYL-5-DEOXY-ß-D-RIBOFURANOSE | |
EP0202111B1 (en) | Antibacterial mycaminosyl tylonolide derivatives and their production | |
CN106892955B (zh) | 一种25-o-葡萄糖基环黄芪醇的合成方法 | |
JP2004536075A (ja) | O−アリルエリスロマイシン誘導体を機能化するためのアリール化方法 | |
CN108822171B (zh) | 一类蒽醌并三氮唑抗生素核苷类似物、合成方法及其在制备抗肿瘤或抗病毒药物中的应用 | |
CN106831924B (zh) | 一种膜荚黄芪皂苷ⅱ的合成方法 | |
CN113929726B (zh) | 一种罗汉果醇衍生化合物及其制备方法和应用 | |
JP4267448B2 (ja) | ソラナムグリコシドの合成方法 | |
CN108299523B (zh) | 一种二糖及制备方法以及一种多聚糖的制备方法 | |
CN111978360B (zh) | 石莼b3s型硫酸寡糖类化合物及其制备方法和应用 | |
CN1115347C (zh) | 一种利用一步或两步随机化反应制备皂甙库的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200103 |
|
CF01 | Termination of patent right due to non-payment of annual fee |